Deals, Partnering

Pfizer receives backing for late-stage trial of kidney cancer drug in Asia

Posted on 10 January 2012

Tags: , , ,

SFJ Pharma has entered into a collaborative development agreement with Pfizer to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy. 

SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities for the adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy.

SFJ will be eligible to receive milestone payments under the agreement.

In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFJ will receive earn- out payments under the agreement.

In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFJ will receive earn- out payments under the agreement. "We appreciate the opportunity to collaborate with Pfizer for one of their most promising oncology compounds," said Robert DeBenedetto. "We believe SFJ's new co-development model will benefit patients by allowing Pharma companies like Pfizer to develop even more compounds simultaneously."

"We recognize the need to look for new and innovative ways to advance our clinical programs and bring our many promising compounds to patients with speed and quality, wherever they are in the world," said Garry Nicholson, president and general manager, Pfizer Oncology. "We are pleased to be collaborating with SFJ on the continued clinical development of axitinib, and in doing so hope to bring a new adjuvant therapy to patients with this disease."

 

Purchase the on-demand report Partnering Agreements with Pfizer

Get more deal information at Current Agreements (subscription required)

Print Friendly, PDF & Email

Leave a Reply